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S E T T I N G :  Multidrug-resistant tuberculosis (MDR-TB) 
has emerged as a signifi cant public health threat in South 
Africa.
O B J E C T I V E :  To describe treatment outcomes and deter-
mine risk factors associated with unfavorable outcomes 
among MDR-TB patients admitted to the provincial 
TB referral hospital in KwaZulu-Natal Province, South 
Africa.
D E S I G N :  Retrospective observational study of MDR-TB 
patients admitted from 2000 to 2003. 
R E S U LT S :  Of 1209 MDR-TB patients with documented 
treatment outcomes, 491 (41%) were cured, 35 (3%) 
completed treatment, 208 (17%) failed treatment, 223 
(18%) died and 252 (21%) defaulted. Of the total num-
ber of patients with known human immunodefi ciency 
virus (HIV) status, 52% were HIV-infected. Treatment 
failure, death and default each differed in their risk fac-
tors. Greater baseline resistance (aOR 2.3–3.0), prior TB 
(aOR 1.7), and diagnosis in 2001, 2002 or 2003 (aOR 
1.9–2.3) were independent risk factors for treatment fail-
ure. HIV co-infection was a risk factor for death (aOR 
5.6), and both HIV (aOR 2.0) and male sex (aOR 1.9) 
were risk factors for treatment default. 
C O N C L U S I O N :  MDR-TB treatment outcomes in 
K waZulu-Natal were substantially worse than those pub-
lished from other MDR-TB cohorts. Interventions such 
as concurrent antiretroviral therapy and decentralized 
MDR-TB treatment should be considered to improve 
MDR-TB outcomes in this high HIV prevalence setting.
K E Y  W O R D S :  drug resistance; Mycobacterium tubercu-
losis; treatment outcomes; South Africa
MULTIDRUG-RESISTANT tuberculosis (MDR-TB), 
defi ned as Mycobacterium tuberculosis resistant to at 
least isoniazid (INH) and rifampicin (RMP), is a rap-
idly emerging disease characterized by diffi culties in 
treatment and high rates of morbidity and mortality. 
There were an estimated 489 000 new cases of MDR-
TB worldwide in 2006, of which only a small frac-
tion were ever diagnosed and treated.1 Although many 
countries have increased efforts to provide MDR-TB 
treatment, the recent global emergence of extensively 
drug-resistant tuberculosis (XDR-TB, defi ned as MDR-
TB with resistance to a fl uoroquinolone and either 
kanamycin [KM], amikacin [AMK] or capreomycin 
[CPM]) has highlighted the possibility that it may be 
worse to provide inadequate treatment for MDR-TB 
than to provide no treatment at all. To prevent mis-
management of MDR-TB, the Green Light Commit-
tee (GLC) was established in 2000 to provide access 
to affordable treatment and quality control for na-
tional MDR-TB programs. In 2006, however, fewer 
than 10% of patients treated for MDR-TB received 
their care in GLC-approved programs.2 The quality 
of care in non-GLC programs is therefore of consid-
erable concern. 
The province of KwaZulu-Natal, South Africa, has 
one of the largest burdens of MDR-TB worldwide, 
with an estimated prevalence of 30 MDR-TB cases 
per 100 000 population.3 Although the last system-
atic drug resistance survey in KwaZulu-Natal in 2002 
revealed only a 1.7% prevalence among new tubercu-
losis (TB) patients,4 the MDR-TB caseload rose nearly 
four-fold to over 3000 cases in 2007.3 Furthermore, 
the discovery of XDR-TB in KwaZulu-Natal in 2005 
has focused world attention on the drug-resistant TB 
epidemic in the province and prompted investigations 
into its cause.5 
High default rates for drug-susceptible TB treat-
ment likely resulted in the creation of large numbers 
of MDR-TB strains,4 but the recent exponential rise 
in MDR-TB cases is diffi cult to explain by inadequate 
treatment alone. Primary transmission of MDR-TB 
has probably also played a critical role.6 South Africa 
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Drug susceptibility testing
DST was performed on all positive sputum cultures 
at the KGH laboratory, using Löwenstein-Jensen me-
dia,8 at the following drug concentrations: INH 0.2 
and 1 mg/l, RMP 40 mg/l, EMB 2 mg/l, streptomycin 
(SM) 4 mg/l, ETH 20 mg/l, KM 20 mg/l, ciprofl oxa-
cin 5 mg/l, OFX 2.5 mg/l and thiacetazone 2 mg/l.
Data collection
Baseline information, including demographics, HIV 
status, prior history of TB and TB DST results, was 
entered into a database for all patients admitted to 
KGH. Information regarding treatment outcome was 
updated by the hospital data manager at hospital dis-
charge and periodically thereafter. 
Treatment outcome defi nitions
MDR-TB treatment outcome was classifi ed accord-
ing to standardized defi nitions.9 Briefl y, cure was de-
fi ned as completion of treatment with consistently 
negative cultures in the fi nal year of treatment. Com-
pletion of the treatment course without bacteriologic 
documentation of cure was considered treatment 
completion. Treatment failure was defi ned as having 
more than one positive culture in the last 12 months 
of treatment. Treatment was also considered to have 
failed if one of the last three cultures taken during 
treatment was positive, or if the patient was persis-
tently culture-positive. Default was defi ned as treat-
ment interruption for ⩾2 consecutive months for any 
reason. Death was defi ned as death from any cause 
during MDR-TB treatment. 
For the purposes of analysis, ‘unfavorable outcome’ 
was defi ned as treatment failure, default or death from 
any cause. Patients who were cured or who success-
fully completed treatment were considered to have 
had a ‘favorable outcome’. 
Statistical analysis
Baseline characteristics and treatment outcomes were 
described using simple frequencies, medians and inter-
quartile ranges (IQR). Bivariate analysis was per-
formed to examine associations between baseline 
characteristics and treatment outcomes using χ2 tests. 
Baseline characteristics examined were age (catego-
rized as ⩽20, 21–30, 31–40, 41–50 and ⩾51 years), 
sex, HIV status, admission year, previous history of 
treatment for TB and employment status. The TB 
drugs to which the initial isolate was resistant were 
examined in several ways: number of drugs (catego-
rized as 2, 3, 4 or ⩾5 drugs), resistance to specifi c 
drugs (e.g., EMB), and combinations of drug resis-
tance (e.g., INH+RMP+EMB+SM). Variables with 
P < 0.1 on bivariate analysis were then incorpo-
rated into a multivariate logistic regression model for 
the composite ‘unsuccessful outcome’ as well as for 
individual unsuccessful outcomes ‘treatment failure’, 
has the world’s largest number of HIV-infected indi-
viduals, and such patients are signifi cantly more likely 
to develop active TB disease following initial infec-
tion.7 High rates of treatment failure or default from 
MDR-TB treatment may have created the ideal mi-
lieu for MDR-TB dissemination. Until 2007, King 
George V Hospital (KGH) in Durban had the only 
TB program in KwaZulu-Natal Province capable of 
treating MDR-TB patients. The program has long been 
under-resourced, and has been left to tackle the rapid 
rise in MDR-TB caseload.
With these factors in mind, we sought to describe 
the treatment outcomes for MDR-TB cases in this high 
HIV prevalence setting at KGH in KwaZulu-Natal, 
South Africa. Specifi cally, we wanted to examine out-
comes prior to the rapid rise in MDR-TB caseload and 
the ‘discovery’ of XDR-TB in 2005. We also sought 
to identify risk factors for unfavorable outcomes of 
MDR-TB treatment to improve the future perfor-
mance of the program.
METHODS
Study setting
KwaZulu-Natal is the most populous of South Af-
rica’s provinces, with approximately 10 million peo-
ple, and the highest HIV prevalence in the country. 
KGH is a 160-bed specialist TB referral center lo-
cated in Durban, KwaZulu-Natal. Until 2007, KGH 
was the only source of treatment for MDR-TB in 
the province. MDR-TB cases from all regions of 
KwaZulu-Natal were referred to KGH for admission 
and management. 
Study population
All patients with culture-proven MDR-TB admitted 
to KGH between 1 January 2000 and 31 December 
2003 were eligible for inclusion. Patients with no 
documented treatment outcome were excluded from 
analysis. 
Management of MDR-TB
KGH used a modifi ed standardized treatment regimen 
for MDR-TB: on admission, patients were started on 
a regimen of KM, ofl oxacin (OFX), pyrazinamide 
(PZA), ethambutol (EMB), and ethionamide (ETH). 
Cycloserine (CYC) was substituted for EMB if the 
isolate had known resistance to EMB. During the 
study period, all patients were admitted until they 
completed the intensive phase of treatment, usually 
4–6 months. They were then discharged home, with 
monthly follow-up at the out-patient clinic at KGH 
and another 18 months of oral treatment (PZA, EMB, 
OFX and ETH) scheduled. The continuation phase 
of therapy was not directly observed. Sputum culture 
and drug susceptibility testing (DST) were performed 
on a monthly basis throughout treatment. 
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‘death’ and ‘default’. Subjects with each of these 
u nsuccessful outcomes were compared to those with 
a favorable outcome. 
As HIV test results were not available for more 
than 40% of the subjects, we performed a sensitivity 
analysis imputing either positive or negative HIV re-
sults for the missing patients, to determine the infl u-
ence of missing HIV data on the effect size of other 
variables in our model. 
The study was approved by the Ethics Committees 
at the University of KwaZulu-Natal and Montefi ore 
Medical Center, Bronx, New York.
RESULTS
From 2000 to 2003, a total of 1261 patients diag-
nosed with MDR-TB were admitted to KGH in Dur-
ban. Fifty-two (4.1%) patients had no recorded fi nal 
outcome and were excluded from the fi nal analysis. 
Baseline characteristics for the remaining 1209 pa-
tients are shown in Table 1. Of these, 472 (39%) were 
women and the median age was 33 years (IQR 26–
41). Information on HIV status was available for 
699 patients (58%), of whom 362 (52%) were HIV-
positive. Information about prior TB was available 
for 1191 (99%) patients, of whom 959 (81%) had a 
history of previous TB. At baseline, 26% of the pa-
tients were resistant only to INH and RMP, while 
32%, 18% and 23% of the patients were resistant to 
respectively 3, 4 and ⩾5 drugs.
Of the 1209 patients with known MDR-TB treat-
ment outcomes, 491 (41%) were cured, 35 (3%) com-
pleted treatment, 208 (17%) failed treatment, 223 
(18%) died while on treatment and 252 (21%) de-
faulted from treatment (Table 2). Overall, 526 (44%) 
had a favorable outcome (cure or completed), while 
683 (56.5%) had an unfavorable outcome (failed, 
died or defaulted). There was no signifi cant differ-
ences in the percentage of patients with a favorable 
treatment outcome from 2000 to 2003 (P = 0.42); 
however, there was a trend towards more patients 
with treatment failure and fewer with default in 2003 
compared with 2000 (Figure).
HIV infection, resistance to three or fi ve TB drugs, 
resistance to EMB, and age between 31 and 40 years 
were all risk factors for the composite ‘unfavorable’ 
outcome, but analysis of individual unfavorable out-
comes revealed that each unfavorable outcome (i.e., 
failure, death or default) had unique, specifi c risk fac-
tors. No one risk factor was found for all three. We 
therefore present risk factor data from multivariable 
analysis for each outcome separately (Table 3).
For treatment failure, previous TB treatment (ad-
justed odds ratio [aOR] 1.7), diagnosis in 2001 (aOR 
2.0), 2002 (aOR 1.9) and 2003 (aOR 2.3), and re-
sistance to either three or fi ve TB drugs (aOR 2.3 
and 3.0, respectively) were all signifi cant indepen-
dent risk factors on multivariable analysis. In con-
trast, the only signifi cant risk factor for death on 
multivariate analysis was HIV co-infection (aOR 5.6). 
Table 1 Baseline characteristics
n (%)
Total 1209
Female  472 (39.0)
Age, years, median [IQR]   33.0 [26–41]
Age, years
 ⩽20  120 (9.6)
 21–30  375 (32.2)
 31–40  373 (30.9)
 41–50  233 (18.4)
 ⩾51  100 (8.6)
HIV status available  699 (57.8)
 HIV-positive  362 (51.8)
 HIV-negative  337 (48.2)
Prior TB treatment status available 1191 (98.5)
 Prior TB  959 (80.5)
 No prior TB  232 (19.5)
Resistant to TB drugs, median [range]    3 [2–9]
 Resistant to 2 drugs  315 (26.1)
 Resistant to 3 drugs  391 (32.3)
 Resistant to 4 drugs  223 (18.4)
 Resistant to ⩾5 drugs  280 (23.2)
Employment status
 Employed  277 (22.9)
 Unemployed  704 (58.2)
 Unknown  228 (18.9)
IQR = interquartile range; HIV = human immunodefi ciency virus; 
TB = tuberculosis.
Table 2 MDR-TB treatment outcomes, 2000–2003
n (%)
Cure  491 (41)
Completed   35 (2.9)
Failed  208 (17)
Died  223 (18)
Defaulted  252 (21)
 Total 1209 (100)
MDR-TB = multidrug-resistant tuberculosis.
Figure Final MDR-TB treatment outcomes by year of diag-
nosis. MDR-TB = multidrug-resistant tuberculosis.
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For treatment default, HIV (aOR 2.0) and male sex 
(aOR 1.9) were the signifi cant risk factors on multi-
variate analysis. Full details of aORs, 95% confi dence 
intervals (95%CIs) and P values for these factors are 
given in Table 3.
Because HIV was a major risk factor for death and 
default, we performed a sensitivity analysis to deter-
mine the infl uence, if any, of the more than 40% of 
patients with unknown HIV status on other risk fac-
tors. Imputation of positive or negative HIV results 
did not signifi cantly affect the direction or magnitude 
of effect of the other covariates in each of the models 
(data not shown). Even when negative results were 
imputed for all of the subjects with unknown HIV 
status, HIV infection remained a very strong predic-
tor of death (P < 0.0001).
DISCUSSION
In this study, we describe treatment outcomes from 
the largest cohort to date of MDR-TB patients re-
ported from a high HIV prevalence setting. Compared 
with published reports from low HIV prevalence set-
tings, treatment outcomes in our cohort were poor, 
with fewer than 45% of patients achieving cure or 
treatment completion.10–16 The unsuccessful outcomes 
were evenly divided among death, treatment failure 
and default, but the risk factors for each outcome 
varied. HIV co-infection was a major risk factor for 
death and default, but not for treatment failure. Con-
versely, a greater number of drugs to which patients 
were resistant, prior TB treatment and later year of 
diagnosis were risk factors for treatment failure, but 
not for death or default. Efforts to improve MDR-
TB outcomes in this setting must therefore be multi-
faceted to address such differing risks.
MDR-TB is a marker of a TB control program’s in-
ability to adequately manage drug-susceptible TB. The 
South African TB program has been severely under-
resourced to handle the three-fold rise in TB caseload 
over the past 15 years. As a result, there is now a 
massive MDR-TB epidemic in KwaZulu-Natal, with 
a prevalence of more than 30 cases per 100 000 pop-
ulation.3,17 Because culture and DST are performed 
only for retreatment cases and patients failing fi rst-
line therapy, these numbers are likely a substantial 
underestimate of the actual current MDR-TB burden. 
Fewer than half of the subjects in our cohort 
achieved cure or treatment completion, making these 
treatment completion rates worse than most prior re-
ports in the published literature. Among 34 published 
MDR-TB cohorts in 20 countries examined in a re-
cent meta-analysis, the pooled treatment success rate 
was 62% (range 40–79%).18 Other published cohorts, 
such as those from California, USA19 and a DOTS-
Plus program in Tomsk, Russia,12 also demonstrate 
treatment success rates of >65%. 
Although most of the published MDR-TB cohorts 
are from low HIV prevalence countries, the inferior 
outcomes in KwaZulu-Natal cannot be explained by 
HIV alone. HIV infection has been associated with un-
successful MDR-TB treatment outcomes, but most of 
these data come from US outbreaks in the 1990s.20–23 
In those reports, the high rates of poor outcome were 
driven almost entirely by deaths, whereas in our 
study, the ‘unfavorable outcomes’ were evenly divided 
among treatment failures, deaths and defaults. Al-
though these three categories are typically combined 
Table 3 Adjusted predictors of unfavorable outcomes








Prior TB  51 (25) 1.7 (1.0–2.8)* 160 (17) 0.6 (0.3–1.1) —† —†
 2001  38 (15) 2.0 (1.1–3.7)*  60 (23) 1.2 (0.6–2.5)  54 (21) 0.7 (0.4–1.3)
 2002  63 (18) 1.9 (1.1–3.4)*  66 (18) 1.5 (0.7–3.0)  78 (22) 0.9 (0.5–1.5)
 2003  87 (23) 2.3 (1.3–4.1)‡  68 (18) 1.5 (0.7–3.0)  64 (17) 0.7 (0.4–1.3)
Number of TB drugs to which
  patient is resistant
 3  78 (20) 2.3 (1.3–4.1)‡ —† —†  89 (23) 1.5 (0.9–2.5)
 4  29 (13) 1.4 (0.7–2.8) —† —†  40 (18) 1.2 (0.6–2.7)
 >5  71 (25) 3.0 (1.5–5.7)‡ —† —†  47 (17) 0.7 (0.3–1.9)
Ethambutol 143 (20) 1.1 (0.7–1.8) 138 (20) 1.5 (0.9–2.4) —† —†
HIV —† —†  90 (25) 5.6 (3.3–9.4)‡  81 (22) 2.0 (1.3–3.1)‡
Male sex —† —† —† —† 175 (24) 1.9 (1.2–3.1)‡
Age, years
 21–30 —† —† —† —†  74 (20) 1.3 (0.6–2.8)
 31–40 —† —† —† —†  91 (24) 1.5 (0.7–3.2)
 41–50 —† —† —† —†  44 (19) 0.8 (0.4–1.8)
 ⩾51 —† —† —† —†  18 (18) 0.9 (0.3–2.7)
* P < 0.05. 
† Non-signifi cant on bivariate analysis.
‡ P < 0.01.
OR = odds ratio; CI = confi dence interval; TB = tuberculosis; HIV = human immunodefi ciency virus.
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and considered together, our data suggest that each 
differed in its risk factors. 
The principal risk factor for failure was baseline 
resistance to a greater number of TB medications; 
nearly 25% of patients in this study were resistant to 
⩾5 drugs. Current MDR-TB guidelines24 emphasize 
using regimens that contain at least four TB drugs to 
which the patients are susceptible. The modifi ed, stan-
dardized treatment regimen at KGH may therefore 
not have had a suffi cient number of active TB drugs 
for patients with such severe drug resistance. Given 
the high rates of treatment failure in our study, con-
sideration should be given either to individualizing 
treatment regimens based on DST results and treat-
ment history, or to increasing the number of medica-
tions in the standardized regimen. 
Our study took place before the availability of 
anti retroviral therapy (ART) in the public sector in 
South Africa, and it is thus no surprise that HIV was 
a risk factor for death. Efforts to reduce mortality 
among MDR-TB patients in high HIV prevalence 
settings should include the integration of ART with 
second-line anti-tuberculosis treatment.25 
The risk factors for default, HIV infection and 
male sex suggest two ends of a spectrum for why in-
dividuals default. A large proportion die, but the treat-
ment program lacks the resources to trace patients 
who miss clinic appointments.26,27 Others improve 
suffi ciently to once again seek employment, often in 
distant cities or provinces. MDR-TB treatment pro-
grams should have the resources to trace and prevent 
defaulters, as treatment interruption is a signifi cant 
cause of amplifi cation of resistance. As a centralized 
treatment program, KGH is unable to trace default-
ers or even provide directly observed therapy in the 
continuation phase, as patients’ homes and communi-
ties are often hundreds of kilometers away. To reduce 
the number of MDR-TB patients defaulting, decentral-
ization of MDR-TB treatment should be considered, 
by creating community-based treatment programs or 
satellite in-patient centers.11,28,29 
Although this cohort demonstrates the burden of 
MDR-TB in KwaZulu-Natal, our study is not with-
out limitations. First, the study was performed retro-
spectively, relying on complete and accurate entry of 
treatment outcomes. Although more than 95% of pa-
tients did have a fi nal outcome reported, we were un-
able to confi rm the accuracy of the data. Second, the 
KGH database provides no information on the use of 
surgical pulmonary resection. An important adjunc-
tive treatment for localized disease, this procedure is 
available to certain patients admitted to KGH and 
may have been an important predictor of treatment 
success.30,31 Third, we were unable to demonstrate 
the development of XDR-TB while patients received 
MDR-TB treatment because end-of-treatment DST 
patterns were not available. Despite the high rates of 
drug resistance in our cohort, only 11 patients had 
XDR-TB on admission. Given the recent alarming 
rates of XDR-TB in KwaZulu-Natal5 and the demon-
stration of nosocomial spread of XDR-TB,6 it is likely 
that the source of the current XDR-TB epidemic was 
one of a few XDR-TB cases seen before 2005 and 
that it was therefore the result of a failing MDR-TB 
treatment program. Fourth, although we did not fi nd 
that HIV was a risk factor for treatment failure, this 
could refl ect a survival bias whereby HIV-infected pa-
tients who were failing therapy died or defaulted be-
fore meeting the outcome criteria for treatment fail-
ure. Finally, nearly 40% of the patients in our cohort 
were not tested for HIV. Public access to antiretrovi-
rals was not available in South Africa until 2004, and 
many patients prior to this were reluctant to be tested 
for HIV. HIV, however, remained a signifi cant predic-
tor of death even when all of the unknown results 
were imputed to be negative.
The incidence of MDR-TB continues to increase in 
KwaZulu-Natal, and although some of this rise may 
be attributed to increased use of sputum culture and 
DST, the additional cases will further tax the TB 
control program. Only by strengthening the MDR 
program with increased staff and resources, provid-
ing integrated treatment for HIV, and addressing the 
many different risk factors for poor treatment out-
comes, will South Africa be able to control this dire 
and growing epidemic. 
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R É S U M É
C O N T E X T E  :   La tuberculose à germes multirésistants 
(TB-MDR) est devenue une menace signifi cative pour la 
santé publique en Afrique du Sud.
O B J E C T I F  :   Décrire les résultats du traitement et déter-
miner les facteurs de risque associés à des résultats défa-
vorables chez les patients atteints de TB-MDR admis à 
l’hôpital provincial de référence TB de la province de 
Kwazulu-Natal, Afrique du Sud. 
S C H É M A  :   Etude observationnelle rétrospective des pa-
tients atteints de TB-MDR admis entre 2000 et 2003.
R É S U LTAT S  :   Sur 1209 patients TB-MDR dont les ré-
sultats du traitement sont documentés, 491 (41%) sont 
guéris, 35 (3%) ont achevé leur traitement, 208 (17%) 
sont des échecs, 223 (18%) sont décédés et 252 (21%) 
sont des abandons. Parmi les patients dont le statut du 
virus de l’immunodéfi cience humaine (VIH) était connu, 
52% sont séropositifs. Les facteurs de risque ont été 
différents pour le traitement avant l’échec, le décès ou 
l’abandon dans chacun des cas. Les facteurs indépendants 
de risque d’échec du traitement sont un taux de résistance 
plus élevé au départ (aOR 2,3–3,0), des antécédents de 
TB (aOR 1,7) et le diagnostic en 2001, 2002 ou 2003 
(aOR 1,9–2,3). La co-infection VIH est un facteur de 
risque de décès (aOR 5,6), et tant le VIH (aOR 2,0) que 
le sexe masculin (aOR 1,9) sont des facteurs du risque 
d’abandon du traitement.
C O N C L U S I O N  :   Les résultats du traitement de la TB-
MDR au Kwazulu-Natal sont substantiellement plus 
mauvais que ceux publiés pour d’autres cohortes de TB-
MDR. Des interventions comme le traitement antirétro-
viral simultané et un traitement décentralisé de la TB-
MDR doivent être envisagées pour améliorer les résultats 
pour la TB-MDR dans ce contexte à haute prévalence 
du VIH.
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M A R C O  D E  R E F E R E N C I A :   La tuberculosis multidrogo-
resistente (TB-MDR) se ha convertido en una amenaza 
considerable de salud pública en Sudáfrica.
O B J E T I V O :   Describir los desenlaces terapéuticos y de-
terminar los factores de riesgo asociados con los desen-
laces desfavorables en pacientes con TB-MDR hospitali-
zados en el hospital de referencia de TB de la provincia 
de KwaZulu-Natal, en Sudáfrica.
M É T O D O :   Fue este un estudio de observación retrospec-
tivo de los pacientes hospitalizados entre 2000 y 2003. 
R E S U LTA D O S :   De los 1209 casos tratados por TB-MDR 
con información sobre el desenlace terapéutico, 491 
(41%) alcanzaron la curación, 35 (3%) completaron el 
tratamiento, 208 (17%) tuvieron un fracaso terapéutico, 
223 (18%) fallecieron y 252 (21%) abandonaron el 
tratamiento. Cincuenta y dos por ciento de los pacientes 
con examen serológico para el virus de la inmunodefi -
ciencia humana (VIH) estaban infectados. Los factores 
de riesgo de fracaso terapéutico, fallecimiento y aban-
dono fueron diferentes. Los factores asociados indepen-
dientemente con el fracaso fueron una mayor farmaco-
resistencia inicial (aOR 2,3–3,0), el antecedente de TB 
(aOR 1,7) y el diagnóstico establecido en 2001, 2002 o 
2003 (aOR 1,9–2,3). La coinfección por el VIH fue un 
factor de riesgo de fallecimiento (aOR 5,6), y la infección 
por el VIH (aOR 2,0) y el sexo masculino (aOR 1,9) 
fueron factores de riesgo de abandono del tratamiento.
C O N C L U S I O N :   Los desenlaces terapéuticos de la TB-
MDR en KwaZulu-Natal fueron signifi cativamente más 
desfavorables que los resultados publicados en otras co-
hortes de pacientes con este tipo de TB. Con el objeto de 
mejorar estos resultados sería importante considerar la 
posibilidad de introducir el tratamiento antirretrovírico 
simultáneo y descentralizar el tratamiento de la TB-
MDR en este entorno de alta prevalencia de infección 
por el VIH.
R E S U M E N
